Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)‘s stock had its “buy” rating reissued by stock analysts at Robert W. Baird in a report issued on Tuesday. They currently have a $40.00 price objective on the specialty pharmaceutical company’s stock. Robert W. Baird’s price objective would suggest a potential upside of 78.57% from the company’s previous close.

Several other research firms also recently issued reports on PRTK. HC Wainwright increased their target price on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, July 17th. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. ValuEngine downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Finally, Raymond James Financial, Inc. restated a “strong-buy” rating and set a $36.00 target price on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Paratek Pharmaceuticals has an average rating of “Buy” and an average target price of $38.11.

Paratek Pharmaceuticals (NASDAQ:PRTK) traded up 0.22% during trading on Tuesday, reaching $22.40. The company’s stock had a trading volume of 371,702 shares. The company’s market cap is $621.85 million. The stock’s 50 day moving average is $25.00 and its 200 day moving average is $22.92. Paratek Pharmaceuticals has a 12 month low of $9.80 and a 12 month high of $29.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $7.50 million.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/robert-w-baird-reiterates-buy-rating-for-paratek-pharmaceuticals-inc-prtk.html.

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc increased its stake in Paratek Pharmaceuticals by 13.3% in the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after acquiring an additional 687 shares during the last quarter. Wells Fargo & Company MN increased its stake in Paratek Pharmaceuticals by 9.9% in the first quarter. Wells Fargo & Company MN now owns 15,566 shares of the specialty pharmaceutical company’s stock valued at $300,000 after acquiring an additional 1,400 shares during the last quarter. ProShare Advisors LLC increased its stake in Paratek Pharmaceuticals by 14.1% in the second quarter. ProShare Advisors LLC now owns 16,191 shares of the specialty pharmaceutical company’s stock valued at $390,000 after acquiring an additional 2,005 shares during the last quarter. Nationwide Fund Advisors increased its stake in Paratek Pharmaceuticals by 22.9% in the second quarter. Nationwide Fund Advisors now owns 13,355 shares of the specialty pharmaceutical company’s stock valued at $322,000 after acquiring an additional 2,492 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Paratek Pharmaceuticals by 7.2% in the second quarter. California State Teachers Retirement System now owns 41,722 shares of the specialty pharmaceutical company’s stock valued at $1,006,000 after acquiring an additional 2,800 shares during the last quarter. 80.52% of the stock is currently owned by hedge funds and other institutional investors.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.